CAPLIPOINT:NSE-Caplin Point Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 907.80

Change

0.00 (0.00)%

Market Cap

INR 68.67B

Volume

0.28M

Avg Analyst Target

INR 695.00 (-23.44%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Caplin Point Laboratories Limited develops, produces, markets, and exports generic pharmaceutical formulations and branded products in India. The company provides liquid and lyophilized injections, ophthalmic products, tablets, liquid orals, capsules, softgel capsules, suppositories and ovules, powder for injection, dry syrups, topicals, inhalers, IV infusions, lyophilized products, branded products, dermo cosmetics, and other products. It also operates QueTenX, an e-commerce website. The company was incorporated in 1990 and is headquartered in Chennai, India. Address: Ashvich Tower, Chennai, India, 600096

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-17 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

N/A

INR2,018.56B 33.66 21.56
DIVISLAB:NSE Divi's Laboratories Limited

N/A

INR1,426.14B 69.59 43.47
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

N/A

INR822.65B 48.08 21.18
PEL:NSE Piramal Enterprises Limited

N/A

INR677.04B 49.31 11.87
CADILAHC:NSE Cadila Healthcare Limited

N/A

INR557.12B 24.56 17.94
ALKEM:NSE Alkem Laboratories Limited

N/A

INR465.43B 28.54 21.09
LUPIN:NSE Lupin Limited

N/A

INR429.72B 26.09 14.15
AUROPHARMA:NSE Aurobindo Pharma Limited

N/A

INR426.07B 8.00 5.01
LAURUSLABS:NSE Laurus Labs Limited

N/A

INR349.33B 33.32 21.30
IPCALAB:NSE Ipca Laboratories Limited

N/A

INR307.26B 30.68 20.49

ETFs Containing CAPLIPOINT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 79.73% 85% B 70% C-
Dividend Return 0.59% 54% F 31% F
Total Return 80.32% 83% B 70% C-
Trailing 12 Months  
Capital Gain 68.41% 66% D 39% F
Dividend Return 0.56% 38% F 21% F
Total Return 68.96% 66% D 39% F
Trailing 5 Years  
Capital Gain 211.96% 81% B- 84% B
Dividend Return 3.13% 66% D 40% F
Total Return 215.09% 81% B- 84% B
Average Annual (5 Year Horizon)  
Capital Gain 13.95% 38% F 54% F
Dividend Return 0.37% 38% F 30% F
Total Return 14.32% 35% F 54% F
Risk Return Profile  
Volatility (Standard Deviation) 45.00% 60% D- 62% D-
Risk Adjusted Return 31.83% 40% F 60% D-
Market Capitalization 68.67B 66% D 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 26.85 47% F 42% F
Price/Book Ratio 5.95 33% F 20% F
Price / Cash Flow Ratio 25.84 40% F 23% F
EV/EBITDA 16.59 50% F 42% F
Management Effectiveness  
Return on Equity 23.28% 73% C 88% B+
Return on Invested Capital 20.98% 79% C+ 91% A-
Return on Assets 14.65% 88% B+ 95% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.43 80% B- 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.